Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics, Inc. (former Nasdaq: SWTX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. Company announcements emphasize its approved medicines OGSIVEO (nirogacestat) for adults with desmoid tumors and GOMEKLI / EZMEKLY (mirdametinib) for adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), as well as its broader pipeline of targeted therapy product candidates for rare tumors and hematological cancers.
News items for SWTX commonly cover clinical and regulatory milestones. For nirogacestat, SpringWorks has reported pivotal and long-term data from the Phase 3 DeFi trial in desmoid tumors, including publications in peer-reviewed journals and analyses of progression-free survival, objective response rates, tumor size reductions and patient-reported outcomes. For mirdametinib, the company has highlighted results from the Phase 2b ReNeu trial in NF1-PN, describing objective response rates, durable tumor volume reductions and improvements in pain and quality of life in both adult and pediatric patients.
Regulatory developments are another frequent theme. SpringWorks has issued releases on FDA approvals of OGSIVEO and GOMEKLI, Orphan Drug designations, and European Commission decisions granting marketing authorization for OGSIVEO and conditional authorization for EZMEKLY. The company also reports on opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and anticipated timelines for European regulatory decisions.
Corporate and transaction news is also prominent. In 2025, SpringWorks and Merck KGaA, Darmstadt, Germany announced a definitive agreement for Merck KGaA, Darmstadt, Germany to acquire SpringWorks, followed by updates on shareholder votes, expected closing timing and the completion of the merger. Financial updates, such as quarterly and annual results, product revenue figures for OGSIVEO, cash position, and pipeline progress, are provided through earnings releases.
Investors and observers following SWTX-related news can use this page to review historical announcements on clinical trial readouts, regulatory approvals, safety information, strategic transactions and pipeline developments associated with SpringWorks Therapeutics.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 17, 2023, SpringWorks Therapeutics and BeiGene presented updated clinical data from a Phase 1b trial focused on the RAF dimer inhibitor, lifirafenib, in combination with the MEK inhibitor, mirdametinib. This trial targets patients with advanced solid tumors driven by genetic mutations in RAS and RAF pathways. The oral presentation at the AACR Annual Meeting highlighted promising early results, indicating a favorable safety profile with low instances of severe adverse events. Among 62 efficacy-evaluable participants, 23% experienced confirmed objective responses, with notable success in specific cancer types, including a 59% response rate in low-grade serous ovarian cancer. The trial is advancing into a dose-expansion phase targeting biomarker-selected patients in late 2023.